Etomidate Exposure Tracks With Worse Early Outcomes After Hip Fracture Surgery
Perioperative etomidate remains attractive in the operating room because it preserves blood pressure better than many alternative induction agents. In frail older adults with hip fracture, however, that hemodynamic advantage now sits beside a concerning signal: exposure was associated with higher 30-day mortality after surgery, along with more pneumonia and major adverse cardiovascular events.
The study used the TriNetX Research Network to examine adults undergoing hip fracture surgery, matching etomidate-exposed patients 1:1 with unexposed controls. After matching, 6,246 patients were included in each group, and baseline characteristics were balanced. The primary endpoint was 30-day mortality; secondary endpoints included pneumonia, sepsis, venous thromboembolism, major adverse cardiovascular events, and acute kidney injury.
The results were not subtle. Etomidate exposure carried an odds ratio of 1.35 for 30-day mortality, with a 95% confidence interval of 1.15 to 1.60 and a P value below 0.001. Pneumonia also increased, with an odds ratio of 1.23, and major adverse cardiovascular events rose as well, with an odds ratio of 1.20. By contrast, acute kidney injury was less frequent in the etomidate group, with an odds ratio of 0.83.
The early postoperative window mattered most. Across 30 to 180 days of follow-up, the associations faded and became non-significant.
Why a Hemodynamically Stable Induction Agent May Still Carry Risk
Etomidate’s reputation in anesthesia rests on cardiovascular stability during induction, a feature that often makes it appealing in older adults who arrive for surgery with limited physiologic reserve. Yet the drug also causes transient adrenal suppression, and that pharmacology provides a plausible explanation for the postoperative pattern seen here. Cortisol signaling supports vascular tone, inflammatory control, and the body’s response to acute surgical stress; transient suppression during a vulnerable perioperative period could contribute to early decompensation, especially in patients already exposed to trauma, blood loss, immobility, and the inflammatory burden of fracture repair.
Hip fracture surgery is not a routine elective procedure. It is a high-risk operation in a population that is often elderly, medically complex, and prone to pulmonary complications, delirium, infection, and cardiovascular instability. A drug that improves induction hemodynamics may still influence the postoperative trajectory if it perturbs endocrine stress responses or interacts with the limited physiologic reserve of these patients. The observed increase in pneumonia and cardiovascular events fits that broader concern, even if the study cannot prove causality.
The lower acute kidney injury rate complicates the picture. Renal hypoperfusion often follows intraoperative instability, so one possible interpretation is that etomidate’s blood pressure preservation may have buffered the kidneys in the immediate perioperative setting. A competing explanation is residual confounding in an observational design, where clinicians may have selected etomidate for patients whose hemodynamics or renal risk profiles differed in ways that matching could not fully remove.
The Short-Term Signal Was Strongest in the First Month
The 30-day findings matter because they align with the biologic timing of perioperative stress. Surgical trauma, immobility, anesthetic exposure, aspiration risk, and early postoperative cardiopulmonary complications all cluster in the days and weeks after hip fracture repair. If adrenal suppression or related physiologic effects contribute to harm, the consequences would be expected to appear early rather than months later. The disappearance of statistical significance during extended follow-up supports that pattern and argues against a durable long-term toxic effect.
Pneumonia deserves special attention in hip fracture populations. Frail patients often have reduced mobility, impaired cough, and limited pulmonary reserve, and any factor that worsens stress response or recovery can tilt the balance toward infection or respiratory decline. Major adverse cardiovascular events likely reflect the same vulnerability, since surgical stress can unmask occult coronary disease, provoke arrhythmia, or destabilize hemodynamics in patients with limited reserve.
The study did not show significant associations for sepsis or venous thromboembolism. Those null results are as important as the positive ones, because they suggest the harm signal was not universal across all postoperative complications. Instead, the pattern concentrated in mortality, pulmonary complications, and cardiovascular events, which may be the domains most sensitive to perioperative physiology and anesthetic choice.
What Anesthesiologists Should Take From the Matched Cohort Data
This analysis does not banish etomidate from practice. It does, however, shift the risk-benefit conversation in hip fracture surgery, where the stakes are high and the margin for physiologic error is narrow. In a patient with severe hypotension or tenuous cardiovascular status, etomidate may still be chosen for induction because alternatives can produce their own dangerous blood pressure drops. But in a population already exposed to trauma and high postoperative complication rates, any drug associated with higher early mortality deserves caution and further scrutiny.
The retrospective design leaves important questions open. Propensity matching can reduce measured confounding, but it cannot eliminate treatment selection bias, unmeasured illness severity, or clinician preference at the bedside. Dosing details, timing of exposure, concurrent anesthetic agents, and granular perioperative management strategies could also influence outcomes, yet those factors are not resolved by this dataset.
What the study does provide is a clinically relevant signal from a large matched cohort: perioperative etomidate exposure tracked with worse short-term outcomes after hip fracture surgery, except for a lower rate of acute kidney injury. Prospective confirmation will be needed before anyone can treat the association as causal, but the signal is strong enough to make anesthetic choice in hip fracture surgery more deliberate, not less.